Roche gets FDA approval for cytomegalovirus diagnostic

Roche ($RHHBY) has snagged its second FDA approval of a diagnostic test this week, this time for a viral infection often found in organ transplant recipients. The agency moved to approve Roche's viral load test for cytomegalovirus (CMV), which uses the company's Cobas AmpliPrep system.

CMV is a potentially deadly disease often transmitted to patients alongside new organs, and Roche's test is a real-time polymerase chain reaction-based assay that the company says will help doctors identify and treat the virus before it has the chance to harm patients.

"With this test, laboratories now have an FDA-approved option for standardized and automated CMV viral load testing that improves the laboratory's workflow." said Paul Brown, head of Roche Molecular Diagnostics, in a statement. "It provides physicians with clinically useful information to aid in the management of solid organ transplant patients with CMV disease."

Roche plans to start shipping the test kit to labs in August.

Earlier this week, the FDA signed off on Roche's new dual-target test for HIV-1, using the Cobas TaqMan platform. All this comes as the Swiss firm has doubled down on its Dx business, announcing last month that it will invest $300 million in its Indiana diagnostics headquarters, planning to add 100 jobs in the process.

- read the Roche release

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.